Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Trade names | Pemgarda |
Other names | VYD222 |
License data |
|
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19. [3]
The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024. [3] [4]
In the US, pemivibart is authorized for the pre-exposure prophylaxis (prevention) of COVID‑19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms (88 lb). [3] It is authorized for individuals who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to an individual infected with SARS‑CoV‑2; and who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID‑19 vaccination. [3]
Pemivibart is the international nonproprietary name. [5]
This article incorporates public domain material from the United States Department of Health and Human Services